Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets

Lukas Beumers(German Cancer Research Center), Stefan Wiemann(German Cancer Research Center)
npj Breast Cancer
December 2, 2023
10.1038/s41523-023-00604-4
Cited by 8

Related Papers

MicroRNA‐30c‐2‐3p negatively regulates NF‐κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer
|Molecular Oncology|2015|105
Integrating proteomics into precision oncology
|International Journal of Cancer|2020|30
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets
|Research Square|2023|1